Evolving landscape of glioblastoma research
Wiener klinische Wochenschrift · 2026-09 · 138 (17-18) · 533-544
DOI: 10.1007/s00508-026-02725-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Wiener klinische Wochenschrift, online erschienen am 10.03.2026. Verfasst von Jana Breu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Glioblastoma, Authorship, Brain Neoplasms, Bibliometrics. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund, Vienna Science and Technology Fund, University of Innsbruck and Medical University of Innsbruck.
Abstract (Originalsprache)
Background
Glioblastoma is the most aggressive type of brain tumor. Here, we examine the evolution of glioblastoma treatment and survival across different study types over nearly a century. Furthermore, we map the landscape of glioblastoma research to track the potential influence of publication bias on perceived progress and assess sex disparities in authorship across time, study type and geographic region.
Methods
We analyzed a comprehensive dataset of glioblastoma research published from 1947–2022. A manual review of 19,668 articles yielded 2232 articles passing the inclusion criteria.
Results
Overall, we observed an increased median overall survival (OS, slope = 0.16 months per year, Pearson’s r = 0.23, p = 1.65e-44) for all study types. Nevertheless, reported survival outcomes varied by treatment modality. Only tumor treating fields (fitted median OS from 14.5 to 21.4 months, slope = 0.53 months per year) showed a stronger increase in positive outcomes than radiotherapy with concomitant and adjuvant temozolomide (fitted median overall survival from 12.0 to 20.0 months, slope = 0.31 months per year). Despite making up only 5.6% of all studies, randomized controlled trials had the highest cumulative impact factor and citation count and US-based researchers dominated across all study types (33.9%). Women continued to be underrepresented, particularly as last authors (25.2% female first, 18.5% female last).
Conclusion
The 75 years of reported survival of patients with glioblastoma document a slow increase in overall survival. While research by women as first authors shows an upward trend, gender inequality persists, particularly in the last authorship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
- Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
- Institute of Biomedical Physics, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea (Republic of).
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea (Republic of).
- Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Förderung
- Austrian Science Fund
- Vienna Science and Technology Fund
- University of Innsbruck and Medical University of Innsbruck
Zitieren
APA
Breu, J., Baumann, B., Sa, J. K., Berghoff, A. S., Preusser, M., Nenning, K. H., & Woehrer, A. (2026). Evolving landscape of glioblastoma research. Wiener klinische Wochenschrift, 138(17-18), 533-544. https://doi.org/10.1007/s00508-026-02725-9
Vancouver
Breu J, Baumann B, Sa JK, Berghoff AS, Preusser M, Nenning KH, et al. Evolving landscape of glioblastoma research. Wiener klinische Wochenschrift. 2026;138(17-18):533-544. doi:10.1007/s00508-026-02725-9
BibTeX
@article{Breu2026,
author = {Breu, Jana and Baumann, Bernhard and Sa, Jason K and Berghoff, Anna Sophie and Preusser, Matthias and Nenning, Karl-Heinz and Woehrer, Adelheid},
title = {Evolving landscape of glioblastoma research},
journal = {Wiener klinische Wochenschrift},
year = {2026},
volume = {138},
number = {17-18},
pages = {533--544},
doi = {10.1007/s00508-026-02725-9}
}
EUVIMED